Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib long-term extension study in participants from prior ibrutinib trials
2023-503803-27-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, open-label trial of ibrutinib in mature B-cell lymphoma and chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of participants affected by an adverse event. Planned start Oct 2013; status: authorised.
02
Drugs
ibrutinib
03
Conditions
mature B-cell lymphomachronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2023-503803-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503803-27-00.